Copine 1 predicts poor clinical outcomes by promoting M2 macrophage activation in ovarian cancer Authors: Bo Sheng, Bo Zhao, Yue Dong, Jiamin Zhang, Suni Wu, Huihui Ji, Xueqiong Zhu Published: 2023 ABSTRACT AbstractObjectiveCopine 1 (CPNE1), a membrane-binding protein, influences the prognosis of various cancers. According to cBioPortal, CPNE1 amplification is a prevalent genetic mutation in ovarian cancer but with unknown oncogenic mechanism.MethodsThis study analysed the CPNE1 expression in ovarian cancer using online datasets, as validated by immunohistochemistry (IHC), quantitative polymerase chain reaction (qPCR) and western blotting. Concurrently, the prognostic value of CPNE1 was accessed. Cell Counting Kit-8, colony formation, transwells and xenograft experiments were performed to evaluate the functions of CPNE1 during ovarian cancer carcinogenesis. CPNE1 and its related genes were analysed by g:Profiler and Tumour Immune Estimation Resource. Furthermore, human monocytic THP-1 cells were co-cultured with ES2 cells to investigate the effect of CPNE1 on macrophage polarization.ResultsThe results of bioinformatic analysis, IHC, qPCR and western blotting indicated a higher CPNE1 in ovarian cancer. CPNE1 overexpression demonstrated an association with a poor prognosis of ovarian cancer. Functionally, CPNE1 overexpression increased ES2 and SKOV3 cell proliferation, invasion and migration in vitro and promoted ovarian tumour xenograft growth in vivo, while CPNE1 knockdown led to opposite effects. Additionally, CPNE1 expression demonstrated an association with immune cell infiltration in ovarian cancer, especially macrophage. CPNE1 promoted protumour M2 macrophage polarization by upregulating cluster of differentiation 163 (CD163), CD206 and interleukin-10.ConclusionsOur study revealed that CPNE1 mediated M2 macrophage polarization and provided a therapeutic target for ovarian cancer. Introduction Ovarian cancer is a fatal and prevalent gynaecologic malignancy. Approximately 19 710 women are estimated to be diagnosed with ovarian cancer, with 13 270 related deaths in the United States in 2023 (1). To date, surgery followed by chemotherapy remains the standard care for ovarian cancer. Ovarian cancer is usually diagnosed at an advanced stage with poor overall survival (OS) due to the insufficient available screening approaches and typical symptoms (2). Predominantly, ovarian cancer has a 5-year survival rate of <45% due to chemoresistance and relapse (3). The prognosis of ovarian cancer patients has not significantly improved despite various advances in comprehensive therapies (4). Therefore, exploring novel therapeutic targets and revealing the potential mechanism is essential to improve the survival rate of ovarian cancer patients. The tumour microenvironment (TME) comprises the non-cancerous cells (e.g. immune cells, neurons, endothelial cells, adipocytes and fibroblasts) and non-cellular components (e.g. extracellular matrix, chemokines and cytokines) (5). Tumour-associated macrophages (TAMs) are the essential components of the TME. The constant crosstalk between TAMs and tumour cells influences tumorigenesis, tumour metastasis and therapeutic response (6). Copines are calcium-dependent membrane-binding proteins and are ubiquitously distributed in multiple homo sapiens and plants (7,8). This family of proteins contains two distinctive domains, two C2 domains that regulate the interaction of phospholipids and calcium in the N-terminus and a protein-binding domain (A domain) in the C-terminus (9). Nine members of this protein family have been identified, which are involved in numerous human diseases, such as cancers, inflammations and nervous system diseases (10,11). Copine 1 (CPNE1), the first discovered copine subfamily member, could encode 537 amino acids and is located on chromosome 20q11.21 (12,13). It is mainly present in cell membranes and cytoplasm, which could interact with multiple plasma and membrane proteins via its A domain (14). CPNE1 has been indicated to regulate cell proliferation, migration and differentiation (15,16). Accumulating evidence reports that CPNE1 acts as an oncogene and is elevated in various malignancies, including lung cancer (17), gastric cancer (13), hepatocellular carcinoma (18) and colorectal cancer (19), but the biological function of CPNE1 in cancers remains unclear. An open-source database, cBioPortal, explores multiple aspects of cancer genomics, including gene expression, genetics and proteomics (20). Our study analysed the genetic alterations (including multiple alterations, deep deletion, amplification, structural variant and mutation) of CPNE1 across pan-cancers using the cBioPortal database. The most common CPNE1 gene alterations were amplifications in the colorectal adenocarcinoma and ovarian serous cystadenocarcinoma (Supplementary Figure 1, is available at Carcinogenesis Online). The association between colorectal cancer and CPNE1 has been reported, while the biological function of CPNE1 in ovarian cancer remains unknown. This study evaluated the expression of CPNE1 in ovarian cancer tissues and cells, the prognostic value of CPNE1 expression, the protumour role of CPNE1 in the growth and metastasis of ovarian cancer in vitro and in vivo and mechanisms that support CPNE1-mediated tumour growth. Materials and methods cBioPortal cBioPortal (http://cbioportal.org/) is an open-source platform that hosts over 200 cancer genomics studies for analysing, visualizing and exploring clinical data and multidimensional cancer genomics (20,21). This study analysed CPNE1 genomic alterations in pan-cancers using the ‘TCGA PanCancer Atlas Studies’ database, which included 10 967 samples. To increase the credibility of the research, tumours with a sample size of <100 and non-genetic alteration were excluded. Online data The ovarian cancer cohorts of GSE26712 and GSE36668 were collected from the gene expression omnibus database. GSE26712 contained 10 normal ovarian samples and 185 ovarian cancer samples. GSE36668 contained 4 normal ovarian samples and 4 ovarian cancer samples. Immunohistochemistry (IHC) The Second Affiliated Hospital of Wenzhou Medical University provided the slices of normal and ovarian cancer tissues according to ethics committee approval (2023-K-05-01). The IHC staining was undertaken as we previously reported (22). The primary antibody used in this assay was the anti-CPNE1 (1:200, Bioss, bs-14024R). A microscope (Leica) captured the image of the slices. The percentage of positive cells was scored as 4 (76–100%), 3 (51–75%), 2 (26–50%) and 1 (0–25%). The staining intensity scores of 3, 2, 1 and 0 indicated strong, moderate, weak and no signals, respectively. The final IHC score ranged from 0 to 12 and was classified as low or high expression using the median value by multiplying these two scores. Cell lines and culture The Type Culture Collection of China Centre provided all cells that were maintained under 5% CO2 at 37°C. HEK293T and ES2 cells were cultured in DMEM (Meilunbio, China) plus 10% fetal bovine serum (FBS, Gibco). Normal ovarian cells (IOSE), SKOV3, OVCAR3 and THP-1 cells were maintained in RPMI 1640 medium (Meilunbio, China) containing 10% FBS. All cells were authenticated by short tandem repeat. Western blotting A RIPA Lysis Buffer (Beyotime, China) was used to extract cell protein and western blotting was performed as described previously (23). Anti-CPNE1 (1:1000, Proteintech, 10126-2-AP) and anti-GAPDH (1:4000, Affinity Biosciences, #T0004) were used as primary antibodies. The ChemiScope System (Clinx, China) captured blot images, and ImageJ software was used for band quantification analysis. qRT-PCR Total RNA was obtained using RNA-easy Isolation Reagent (Vazyme, R701-01). A reverse transcription kit (TransGen Biotech, P20607, China) was used for reverse transcription following the manufacturer’s protocol. Tsingke Biotechnology Co., Ltd provided the primers used for PCR as listed in Supplementary Table 1, available at Carcinogenesis Online. Quantitative PCR was performed as described previously (24). The level of relative gene expression was obtained using the 2−ΔΔCT method, which was normalized by GAPDH. The Kaplan–Meier (KM) Plotter database The KM plotter (http://kmplot.com/) is an online database for detecting the effect of genes on the prognosis of multiple cancers. The effect of CPNE1 on progression-free survival (PFS) and OS of ovarian cancer was determined based on the value of median gene expression. Virus production and cell transfection Shanghai Jiao Tong University provided the CPNE1 short hairpin RNAs (shRNAs) plasmids, and the CPNE1 complementary DNA expression vector was purchased from Youbio Biosciences Inc. The sequences of shRNA are described as sh1: 5ʹ-GAATCTATGACATAGACAA-3ʹ, sh2: 5ʹ-GGTCTCAGCTCAGGAATTA-3ʹ and sh3: 5ʹ-CAGGACTATGACTCAGACA-3ʹ. A lentivirus particle was produced in HEK293T by transfecting lentivectors with psPAX2 and pMD2.G. Afterward, the produced virus infected the target cells, and puromycin was added to select infected cells. Western blot verified the efficacy after transfection. Cell Counting Kit-8 (CCK-8) and colony formation assay ES2 and SKOV3 cells (3 × 103 cells/well) were dispensed into a 96-well plate with standard cell media and incubated for 24, 48, 72 and 96 h. The optical density value of each well at 450 nm was detected using a micro-plate reader after each well was added 10 µl of CCK-8 reagent (Meilunbio, China) and incubated at 37°C for 2 h. Colony formation assays were performed with cells (1000/well) being seeded into a 6-well plate and cultured in 10% FBS media for 7 days. The colonies were fixed in paraformaldehyde for 15 min after being washed with PBS twice and were stained with crystal violet for visualization. The experiments were performed three times, and the colonies with >50 cells were analysed. Migration and invasion assays The migration and invasion assays were performed using transwell polycarbonate filters (8 µm pore size). Briefly, cells (1 × 104 for migration and 2 × 104 for invasion) were seeded to the upper inserts with 100 µl of serum-free media. Subsequently, 600 µl of media with 10% FBS was filled in the bottom chambers. Matrigel was precoated on the filter for invasion assays. After 24 h, the upper insert was washed with PBS twice. The membrane was then fixed with paraformaldehyde and stained with crystal violet. An inverted microscope counted and imaged the migrated or invaded cells. Tumour xenograft experiment Twelve female BALB/C nude mice (4 weeks old) were purchased from the Animal Experiment Centre of Wenzhou Medical University and were randomly divided into two groups. ES2 cells (3 × 106 stably transfected with CPNE1 overexpression or corresponding control vector) were subcutaneously injected into the flank of mice. Tumour sizes were measured every 5 days and calculated by the formula: Volume = width2 × length/2. Tumours were dissected and weighed after the mice were euthanized. The Experimental Animal Centre of Wenzhou Medical University approved this animal assay (wydw2022-0572). Protein–protein interaction (PPI) network and enrichment analysis The integrated network of CPNE1 was explored via the compartmentalized protein–protein interaction (ComPPI) database (http://comppi.linkgroup.hu) (25). Additionally, the link gene list of CPNE1 obtained from ComPPI underwent functional profiling analysis using the web-based tool ‘g:Profiler’ (https://biit.cs.ut.ee/gprofiler/) (26). Here, a specific organism was selected ‘human’, and the customized algorithm g:SCS significance threshold set at 0.05 was used for identifying enriched terms. The top terms from five subdatabases, including human phenotype ontology, reactome pathway, molecular function, cellular component and biological process, were separately illustrated in bubble plots using the ‘ggplot2’ R package. Immune infiltration analyses The Tumour Immune Estimation Resource (TIMER) (http://timer.cistrome.org/) is an open platform providing a comprehensive analysis of immune cell infiltration in multiple cancers (27,28). The relationship between immune infiltration and CPNE1 expression in ovarian cancer was obtained from the TIMER database. Macrophage generation and polarization THP-1 cells (1 × 105 cells/well) were dispensed into a 12-well plate and stimulated with phorbol 12-myristate 13-acetate (PMA) (100 ng/ml, MedChemExpress) for 24 h to generate M0 macrophages. M0 macrophages were then co-cultured with ES2 cells (ES2 CPNE1-overexpression or its corresponding empty vectors) in a co-cultivation system (0.4-µm pore size, LABSELECT, China) to mimic the generation of TAMs. The co-cultured TAMs were obtained after 72 h for further analysis. Immunofluorescence staining (IF) Cells were fixed with 4% paraformaldehyde at room temperature for 30 min and washed three times with 0.1% Triton/PBS. The cells were then covered with blocking buffer and incubated overnight with a rabbit anti-CD206 antibody (1:100, Proteintech, 18704-1-AP) or mouse anti-CD86 antibody (1:100, Santa Cruz Biotechnology, sc-28347) at 4°C. After being washed with PBS thrice, cells were incubated with Alexa Fluor® 594 (red) anti-rabbit IgG or Alexa Fluor® 488 (green) anti-mouse IgG for 1 h at 37°C. A fluorescence microscope was used to acquire images after staining the cells with DAPI. Statistical analysis Data were presented as the mean ± standard deviation. Differences among groups were evaluated by Student’s t-test, Mann–Whitney test and one-way analysis of variance with GraphPad Prism 6.0. The association of CPNE1 expression with clinicopathological characteristics was analysed using Fisher’s exact test. P < 0.05 was considered statistical significance. Results CPNE1 expression is upregulated in ovarian cancer Genetic mutations and copy number aberration alter gene expression patterns of cancer cells, which is closely associated with tumour progression. Thus, we first investigated genetic alterations (including multiple alterations, deep deletion, amplification, structural variant and mutation) of CPNE1 across pan-cancers using the cBioPortal analysis. In the TCGA cohorts, genetic alterations in CPNE1 were predominantly caused by mutation and amplification of pan-cancers, and near 4% of CPNE1 alterations (including ‘amplification’ and ‘missense mutation’) were observed in ovarian cancer patients (Supplementary Figure 1, is available at Carcinogenesis Online). The results strongly indicated the upregulation of CPNE1 effected the development of ovarian cancer. GSE26712 and GSE36668 were then selected to further explore the expression profile of CPNE1 in ovarian cancer. The results indicated higher CPNE1 messenger RNA (mRNA) levels in tumour samples relative to normal ovarian samples (Figure 1A and B). IHC analysis was then conducted via our clinical samples to further validate the different CPNE1 expressions between normal ovary and ovarian cancer tissues at the protein level. Figure 1C shows the representative images, and CPNE1 is localized in the cytoplasm. Higher CPNE1 expression was evident in ovarian cancer tissues relative to normal tissues (Figure 1D). However, high CPNE1 staining showed no significant association with age, clinical stage and lymph node metastasis of ovarian cancer patients (Supplementary Table 2, available at Carcinogenesis Online). The mRNA and protein levels of CPNE1 were both higher in ovarian cancer cell lines (OVCAR3, SKOV3 and ES2 cells) compared with IOSE (Figure 1E–G). Overall, these findings indicated that CPNE1 was upregulated in ovarian cancer tissues and cells. Upregulated CPNE1 expression in ovarian cancer. (A and B) The mRNA level of CPNE1 in ovarian cancer and normal tissues from GSE26712 (A) to GSE36668 (B). (C) Representative images of IHC staining with anti-CPNE1 antibody in ovarian cancer and normal tissues. (D) The IHC score of CPNE1 protein in ovarian cancer and normal tissues. (E) The expression of CPNE1 mRNA in IOSE and ovarian cancer cells as shown by PCR. (F) The expression of CPNE1 protein in IOSE and ovarian cancer cells as shown by western blotting. (G) The quantitative analysis of (F). *P < 0.05, **P < 0.01, ***P < 0.001. CPNE1 predicts a poor prognosis in patients with ovarian cancer The KM plotter was used to evaluate the prognostic significance of CPNE1 for patients with ovarian cancer. Patients with a high CPNE1 level had a worse OS and PFS than those with a low CPNE1 level in ovarian cancer (Supplementary Figure 2A and B, available at Carcinogenesis Online). Similarly, patients with higher mRNA levels of CPNE1 showed a worse prognosis in terms of OS and PFS in serous ovarian cancer (Supplementary Figure 2C and D, available at Carcinogenesis Online). Furthermore, CPNE1 elevation was correlated with an unfavourable PFS in endometrioid ovarian cancer, whereas CPNE1 was not correlated with OS (Supplementary Figure 2E and F, available at Carcinogenesis Online). We then assessed the role of CPNE1 among different pathological grades in ovarian cancer patients. The results indicated that increased CPNE1 predicted a worse OS and PFS in ovarian cancer patients with high and poor differentiation (Supplementary Table 3, available at Carcinogenesis Online). However, increased CPNE1 demonstrated no correlation with patients having ovarian cancer with moderate differentiation. Concerning clinical stages of ovarian cancer, CPNE1 mRNA expression was positively correlated with a worse PFS in women with ovarian cancer at all stages. Remarkably, CPNE1 mRNA expression correlated with a poor OS in patients with stages III + IV ovarian cancer, while CPNE1 had no association with OS in patients with stages I + II ovarian cancer (Supplementary Table 4, available at Carcinogenesis Online). Knockdown of CPNE1 in ES2 and SKOV3 cells inhibited proliferation motility, invasion and migration The ES2 and SKOV3 cells demonstrated relatively high CPNE1 levels, thus the stable CPNE1 knockdown in these cells were established to evaluate its function. The ES2 and SKOV3 cells were infected with lentivirals that contain CPNE1 shRNAs (sh1, sh2 and sh3) or normal control (NC). The efficacy of CPNE1 knockdown was verified by western blot, and the results indicated a significantly reduced protein expression of CPNE1 by infecting with shRNAs (Figure 2A and B). We selected sh1 and sh2-CPNE1 for further experiments based on the efficacy of CPNE1 knockdown. First, the cell viability was explored by CCK-8 assay, which revealed that cell viability was strongly suppressed in both ES2 and SKOV3 cells after CPNE1 knockdown compared with the NC group (Figure 2C). Similarly, a colony formation assay was performed to assess the function of CPNE1 on cell proliferation, and it revealed that CPNE1-deficient cells formed significantly fewer colonies (Figure 2D and E). Next, the roles of CPNE1 in the invasion and migration of those cells were examined by transwell assay. Our results revealed that CPNE1 knockdown inhibited the invasion and migration ability of ES2 and SKOV3 cells (Figure 2F and G). These data strongly indicated that CPNE1 knockdown suppressed the proliferation motility, invasion and migration of ovarian cancer cells. CPNE1 knockdown in ES2 and SKOV3 cells inhibits proliferation motility, invasion and migration. (A) Western blot analysis of CPNE1 knockdown efficacy in ES2 and SKOV3 cells. (B) The quantitative analysis of (A). (C–E) The effect of CPNE1 knockdown on cell viability in ES2 and SKOV3 cells was detected via CCK-8 assay (C) and colony formation (D, E). (F and G) The number of invasive cells (F) and migratory cells (G) in the control and CPNE1-knockdown groups. *P < 0.05, **P < 0.01, ***P < 0.001. CPNE1 promotes the vitality and mobility of ES2 and SKOV3 cells We selected ES2 and SKOV3 to construct CPNE1 overexpression cell lines for the subsequent experiments to confirm the effect of CPNE1 overexpression. Western blot confirmed the CPNE1 overexpression. The CPNE1 expression in transfected cells was significantly elevated (Figure 3A and B). Cell viability and colony formation were enhanced by CPNE1 overexpression in both ES2 and SKOV3 cell lines (Figure 3C–E). Additionally, the transwell assay was conducted to validate the effect of CPNE1 on the invasion and migration capabilities of ES2 and SKOV3 cells. The invaded and migrated cells were increased in the CPNE1 overexpression group than in the control group (Figure 3F and G). Our results indicated that CPNE1 might be a tumour promoter in ovarian cancer. CPNE1 promotes cell proliferation, invasion and migration of ES2 and SKOV3 cells. (A) CPNE1-overexpressing ES2 and SKOV3 cells were constructed and confirmed via western blot. (B) The quantitative analysis of (A). (C–E) The effect of CPNE1 overexpression on cell viability in ES2 and SKOV3 cells was detected via CCK-8 assay (C) and colony formation (D, E). (F and G) The number of invasive (F) and migratory (G) cells in the control group and CPNE1-overexpression group. *P < 0.05, **P < 0.01, ***P < 0.001. CPNE1 overexpression promotes tumour growth in nude mice ES2 cells with CPNE1 overexpression and its corresponding empty vectors were hypodermically injected into nude mice to further validate the protumour function of CPNE1 in vivo. A significant increase was seen in both the tumour volume and weight of the CPNE1 overexpression group compared with the control group (Figure 4A–D). Overall, CPNE1 facilitated tumour growth and contributed to ovarian cancer progression. CPNE1 overexpression promotes tumour growth in nude mice. (A) Photograph of CPNE1-overexpression ES2 xenografts (up) relative to the control (down). (B–D) The growth curves (B), final volume (C) and weight (D) of xenograft tumours in the CPNE1-overexpression and control groups. OE: CPNE1-overexpression. *P < 0.05. CPNE1 and its related genes regulate immunity in ovarian cancer The PPI network was implemented using the interaction data obtained from ComPPI to comprehensively understand the CPNE1 protein. The result indicated that CPNE1 interacted with numerous proteins, and the subcellular localisations of those proteins were distributed in the membrane, extracellular, secretory pathway, nucleus, mitochondrion and cytosol (Figure 5A). Enrichment analysis revealed the primary involvement of these genes in cellular and metabolic processes (Supplementary Figure 3A, available at Carcinogenesis Online). Kyoto Encyclopaedia of Genes and Genomes pathway analysis revealed that these genes regulated the cancer-related pathways and genetic mutations, such as MAPK signalling pathway, RAS mutants and moderate kinase activity BRAF mutants (Supplementary Figure 3B, available at Carcinogenesis Online). Moreover, Human Phenotype Ontology analysis indicated these genes were involved in abnormality of the immune system (Figure 5B). The relationship between immune infiltration and CPNE1 expression in ovarian cancer was further examined using TIMER data. The correlation coefficients between multiple types of immune cells and CPNE1 expression were explored using Spearman tests. The dataset revealed the positive correlation of CPNE1 expression with tumour purity (P < 0.05, cor = 0.156), as well as a statistical correlation between CPNE1 expression and macrophage (P < 0.05, cor = 0.177) and B cell (P < 0.05, cor = −0.126) infiltration in ovarian cancer (Figure 5C). The correlation between subtypes of those two cells and CPNE1 expression was further explored. The result showed CPNE1 expression was positively associated with naïve and plasma B cells while negatively correlated to class-switched memory B cell in ovarian cancer (P < 0.05) (Figure 5D). Interestingly, the result revealed that CPNE1 expression was positively correlated with M2 macrophage while negatively related to M1 macrophage (Figure 5E). Altogether, CPNE1 expression was closely linked to the infiltration of immune cell in ovarian cancer, especially macrophage. CPNE1 and its related genes regulate immunity in ovarian cancer. (A) The protein–protein interaction (PPI) network presented the proteins interacting with CPNE1. (B) Human Phenotype Ontology analysis of CPNE1 and its related genes. (C) Correlations between CPNE1 and multiple immune infiltrations. (D) Correlations between CPNE1 and B cell subtypes in ovarian cancer. (E) Correlations of CPNE1 and macrophage subtypes in ovarian cancer. CPNE1 promotes M2 polarization of TAMs via upregulating CD163 and CD206 To verify the upper conclusions, an in vitro model of TAMs was developed. Human THP-1 monocytes were treated with PMA for 24 h to differentiate into M0 macrophages and then co-cultured for 72 h with ES2 cells to generate TAMs (Figure 6A). PMA incubation induced THP-1 cells to adherent growth (Figure 6B). The mRNA levels of the macrophage marker cluster of differentiation 68 (CD68) were increased in the M0 group relative to the THP-1 group, which further indicated the successful M0 macrophage generation (Figure 6C). The mRNA levels of CD163, CD206 and interleukin-10 (IL-10) of TAMs after being co-cultured with different ES2 cells (ES2 CPNE1-overexpression or its corresponding empty vectors) were markedly upregulated in the TAMCPNE1-OE group compared with the TAMNC group (Figure 6D). However, the mRNA levels of CD86 and IL-6 in the TAMCPNE1-OE group were significantly lower than those in the TAMNC group (Supplementary Figure 4A, available at Carcinogenesis Online). Immunofluorescence experiments further verified that TAMs displayed lower expression of M1 macrophage marker, CD86 and higher expression of M2 macrophage marker, CD206, in the TAMCPNE1-OE group (Figure 6E and Supplementary Figures 4B, available at Carcinogenesis Online). CPNE1 overexpression could significantly upregulate the CD206 level and downregulate the CD86 level in TAMs. CPNE1 promoted M2 polarization of TAMs in ovarian cancer due to CD163 and CD206 upregulation. CPNE1 promotes M2 polarization of TAMs by upregulating CD163 and CD206. (A) Experimental diagram of generating TAMs. (B) The morphology of THP-1 after co-culturing with PMA. (C) The mRNA level of macrophage marker CD68 in M0 macrophages compared with THP-1 cells, as shown by PCR. (D) The mRNA level of M2 macrophage markers (CD163, CD206 and IL-10) in the TAMCPNE1-OE group compared with the TAMNC group, as shown by PCR. (E) Immunofluorescence staining of CD206 in macrophages after co-culturing with different ES2 cells (ES2 CPNE1-overexpression or its corresponding empty vectors). **P < 0.01, ***P < 0.001. Discussion Accumulated evidence indicated that CPNE1 is critically involved in multiple cancers (10). Meanwhile, high CPNE1 expression is linked to poor prognosis in various human malignancies, such as prostate cancer (29), renal cell carcinoma (30) and osteosarcoma (15). However, the biological role of CPNE1 in ovarian cancer remains unclear. Our study first emphasized that higher CPNE1 expression was evident in ovarian cancer tissues compared with normal tissues. Ovarian cancer cell lines also demonstrated higher CPNE1 levels compared with IOSE. Additionally, the KM analysis indicated that the elevated CPNE1 level predicted a worse OS and PFS in patients with ovarian cancer. All these results indicate that CPNE1 contains oncogenic characteristics and could serve as a prognostic factor for patients with ovarian cancer. The biological function of CPNE1 in promoting lung cancer was clearly demonstrated (10). CPNE1 overexpression elevated cell metastasis and proliferation in lung adenocarcinoma (31). Concurrently, CPNE1 was identified as a target of miR-335-5p and miR-195-5p, which could promote lung cancer cell proliferation and migratory abilities (17,32). CPNE1 degradation was mainly regulated by the ubiquitin ligase NEDD4L in lung cancer (33). Moreover, CPNE1 interacted with RACK1 and further induced mesenchymal-epithelial transition tyrosine kinase receptor (MET) signalling activation to facilitate tumorigenesis (34). Consistently, CPNE1 was reported to promote colorectal cancer cell growth and facilitate chemoresistance of oxaliplatin (19). Additionally, CPNE1 upregulation enhanced the cell viability, cell motility and radioresistance in breast cancer cells by regulating AKT activation (35,36). CPNE1 could promote the progression of several tumours by acting as an oncogene, whereas CPNE1 knockdown produced the opposite effects. CPNE1 silencing could effectively inhibit tumour proliferation, arrest the cell cycle and accelerate cell apoptosis by suppressing the MAPK pathway (13). Additionally, CPNE1 knockdown suppressed cell viability and metastasis in human osteosarcoma (15). The biological function of CPNE1 in ovarian cancer is rarely reported. Our study indicated that CPNE1 silencing inhibited the proliferation and migratory abilities of ES2 and SKOV3 cells. CPNE1 overexpression promoted ovarian cancer cell viability, invasion and migration, as well as xenograft tumour growth, to support its oncogenetic functions. Genetic alterations play crucial roles in ovarian cancer initiation, and BRCA mutation carriers face a high risk of ovarian cancer, while the underlying mechanism is unclear (37). Concurrently, accumulating evidence indicates that TME regulates ovarian cancer initiation and modulates ovarian cancer progression (38). The expression of CPNE1 was linked to immune response and positively correlated with immune cell infiltration, such as macrophage, dendritic cell, T cell and neutrophil in hepatocellular carcinoma (18). Additionally, CPNE1 expression and immune infiltration in renal carcinomas were significantly associated. Meanwhile, CPNE1 was positively related to higher T cell exhaustion marker levels (LAG3, CTLA4 and PDCD1), and it negatively responded to immunotherapy (39). Similarly, the analysis of data from ComPPI in our study revealed that CPNE1 possessed a regulatory effect on immunity in ovarian cancer. In particular, elevated CPNE1 expression was associated with macrophage and B cell infiltrations in ovarian cancer. TAMs, the main components of TME that refer to the macrophages in TME, facilitate multiple cancer progression (40). Generally, TAMs are categorized into M1 phenotype and M2 phenotype. M2 macrophages are tumour promoting, while M1 macrophages are proinflammatory and are identified as anti-tumour (41). Hence, TAMs primarily exhibit the M2 phenotype and are related to poor prognosis. CD163 is a haemoglobin scavenger receptor while CD206 is a macrophage mannose receptor 1. They all act as common M2 macrophage markers. Our study revealed significantly elevated CD163 and CD206 expressions in TAMs after co-culturing with CPNE1-overexpressed ES2 cells compared with control cells. Previously mentioned evidence indicates the importance of the CPNE1 protein for macrophage polarization and TAM formation. Similar to other CPNEs, CPNE1 has two N-terminal C2 domains and one C-terminal A domain. The C2 domain is a calcium-dependent phospholipid-binding activity, which may be involved in vesicle transport, membrane trafficking and cell signalling pathways. The A domain functions as a protein-binding domain and interacts with multiple extracellular and intracellular proteins, which indicates the involvement of CPNE1 in a wide variety of cellular processes (10). Various proteins have been identified as CPNE1 targets, including AKT (17), MEK (15), RACK1 (34) and ERK (17), which have been reported to influence carcinogenesis and TME (42,43). In our study, the result of PPI network also indicated that CPNE1 could interact with numerous proteins. Altogether, we speculate that CPNE1 may interact with its target proteins to promote ovarian cancer progression and M2-like macrophage polarization via its C2 and A domains. However, the underlying mechanisms require further investigation. Meanwhile, some limitations exist in this study. Our findings confirmed that CPNE1 could affect macrophage polarization in ovarian cancer. More investigations are needed to determine the effects of CPNE1 in ovarian cancer progression, as well as its exact regulation mechanism for tumour immune infiltration. Conclusion In conclusion, our results indicate that CPNE1 promotes M2 macrophage activation to accelerate ovarian cancer progression and predicts a poor clinical outcome. The targeting of CPNE1 may be a new therapeutic approach for ovarian cancer. Supplementary Material Click here for additional data file. Acknowledgement The Figure 6A and Graphical Abstract were created with BioRender.com. Glossary Abbreviations: Copine 1 immunohistochemistry overall survival tumour-associated macrophages tumour microenvironment Contributor Information Bo Sheng, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Bo Zhao, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Yue Dong, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Jiamin Zhang, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Suni Wu, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Huihui Ji, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Xueqiong Zhu, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Funding This study was supported by the Scientific Research Fund of Zhejiang Provincial Education Department and Zhejiang Key Laboratory of Traditional Chinese Medicine for Diagnosis and Treatment of Gynecological Cancers (2022-11). Conflict of Interest Statement None declared. Data availability The data that support the findings of this article are available from the corresponding author upon reasonable request. Author contributions Xueqiong Zhu and Huihui Ji conceived the idea and designed the experiment; Bo Sheng and Bo Zhao carried out experiments and analysed the data; Yue Dong, Jiamin Zhang and Suni Wu participated in data analysis; Bo Sheng prepared figures and tables and wrote the manuscript. Xueqiong Zhu and Huihui Ji revised the manuscript. All authors have read and agreed to the published version of the manuscript. References Associated Data Supplementary Materials Click here for additional data file. Data Availability Statement The data that support the findings of this article are available from the corresponding author upon reasonable request.